fampridine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4163 504-24-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fampyra
  • dalfampridine
  • ampyra
  • pyridin-4-amine
  • 4-aminopyridine
  • fampridine
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.
  • Molecular weight: 94.12
  • Formula: C5H6N2
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: 0.46
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90.30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.04 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 2010 FDA ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1791.47 14.85 787 36003 42177 50526157
Urinary tract infection 1388.49 14.85 1207 35583 222813 50345521
Laboratory test abnormal 1004.39 14.85 437 36353 22771 50545563
Balance disorder 701.52 14.85 504 36286 70086 50498248
Multiple sclerosis 674.55 14.85 319 36471 20174 50548160
Fall 611.71 14.85 963 35827 333969 50234365
Urine analysis abnormal 595.92 14.85 191 36599 4159 50564175
Gait disturbance 554.41 14.85 611 36179 149394 50418940
Therapy cessation 475.64 14.85 273 36517 25738 50542596
Muscular weakness 378.39 14.85 403 36387 94610 50473724
Seizure 265.39 14.85 375 36415 117499 50450835
Insomnia 222.38 14.85 430 36360 174435 50393899
Escherichia urinary tract infection 216.77 14.85 119 36671 10276 50558058
Muscle spasticity 215.88 14.85 142 36648 17042 50551292
Peroneal nerve palsy 195.98 14.85 84 36706 4199 50564135
Gait inability 176.07 14.85 173 36617 36854 50531480
Dizziness 155.53 14.85 578 36212 345791 50222543
Lymphocyte count decreased 152.06 14.85 137 36653 26170 50542164
B-lymphocyte count decreased 149.81 14.85 46 36744 864 50567470
Secondary progressive multiple sclerosis 146.72 14.85 49 36741 1217 50567117
Memory impairment 143.40 14.85 228 36562 79132 50489202
Inappropriate schedule of product administration 139.01 14.85 213 36577 71618 50496716
Central nervous system lesion 137.97 14.85 86 36704 9403 50558931
Hypoaesthesia 136.68 14.85 292 36498 126965 50441369
Therapeutic response unexpected 133.87 14.85 103 36687 15812 50552522
Flushing 131.48 14.85 200 36590 66815 50501519
Rheumatoid arthritis 129.11 14.85 4 36786 202546 50365788
Culture urine positive 126.71 14.85 58 36732 3393 50564941
Paraesthesia 124.63 14.85 272 36518 119971 50448363
Asthenia 121.67 14.85 506 36284 318536 50249798
Toxicity to various agents 117.40 14.85 10 36780 212489 50355845
Drug ineffective 114.43 14.85 997 35793 818336 49749998
Urine leukocyte esterase positive 113.91 14.85 51 36739 2832 50565502
Micturition urgency 107.94 14.85 70 36720 8194 50560140
Dyspnoea 106.53 14.85 146 36644 547462 50020872
Mobility decreased 105.55 14.85 200 36590 79748 50488586
Pollakiuria 105.17 14.85 107 36683 23744 50544590
Off label use 95.76 14.85 123 36667 474303 50094031
Lymphopenia 95.52 14.85 84 36706 15537 50552797
Urinary incontinence 93.71 14.85 109 36681 28099 50540235
JC polyomavirus test positive 90.31 14.85 33 36757 1076 50567258
Anaemia 89.19 14.85 36 36754 252420 50315914
Systemic lupus erythematosus 88.78 14.85 3 36787 140619 50427715
Product substitution issue 84.77 14.85 75 36715 13982 50554352
Depression 84.15 14.85 288 36502 165135 50403199
Head injury 83.46 14.85 95 36695 23925 50544409
Trigeminal neuralgia 82.94 14.85 42 36748 3073 50565261
T-lymphocyte count increased 79.75 14.85 18 36772 91 50568243
Completed suicide 79.29 14.85 4 36786 131885 50436449
Walking aid user 77.96 14.85 52 36738 6381 50561953
Dysstasia 75.04 14.85 78 36712 17741 50550593
CD4 lymphocytes increased 74.27 14.85 18 36772 130 50568204
Joint swelling 73.00 14.85 44 36746 245242 50323092
T-lymphocyte count decreased 72.61 14.85 20 36770 251 50568083
Progressive multiple sclerosis 71.03 14.85 25 36765 730 50567604
Neurogenic bladder 68.79 14.85 36 36754 2821 50565513
Motor dysfunction 67.58 14.85 52 36738 7979 50560355
Exposure during pregnancy 65.96 14.85 6 36784 121009 50447325
Acute kidney injury 64.97 14.85 43 36747 228015 50340319
Glossodynia 62.27 14.85 6 36784 115563 50452771
Infusion related reaction 61.79 14.85 23 36767 169534 50398800
Movement disorder 61.70 14.85 70 36720 17562 50550772
Bladder disorder 61.64 14.85 48 36742 7495 50560839
Red blood cells urine positive 61.26 14.85 33 36757 2742 50565592
Dysgraphia 59.60 14.85 32 36758 2641 50565693
Influenza like illness 58.33 14.85 129 36661 57330 50511004
Arthralgia 57.71 14.85 148 36642 438554 50129780
Neutropenia 57.50 14.85 18 36772 147947 50420387
CD4 lymphocytes decreased 57.13 14.85 25 36765 1314 50567020
White blood cells urine positive 55.46 14.85 37 36753 4541 50563793
Primary progressive multiple sclerosis 55.44 14.85 13 36777 80 50568254
Gait spastic 55.15 14.85 16 36774 245 50568089
Product use issue 54.92 14.85 20 36770 149455 50418879
Contraindicated product administered 54.62 14.85 20 36770 148938 50419396
Maternal exposure during pregnancy 54.43 14.85 24 36766 159754 50408580
CD8 lymphocytes decreased 53.36 14.85 14 36776 144 50568190
Muscle spasms 51.51 14.85 204 36586 125349 50442985
Loss of control of legs 51.35 14.85 23 36767 1278 50567056
Treatment failure 51.28 14.85 18 36772 137619 50430715
Temperature intolerance 51.08 14.85 43 36747 7496 50560838
Product dose omission issue 50.97 14.85 266 36524 183572 50384762
Hypotension 50.59 14.85 58 36732 235411 50332923
Febrile neutropenia 50.24 14.85 6 36784 97661 50470673
Magnetic resonance imaging abnormal 48.22 14.85 28 36762 2690 50565644
Epilepsy 47.48 14.85 68 36722 21499 50546835
Wound 46.57 14.85 10 36780 105784 50462550
Lower respiratory tract infection 46.23 14.85 7 36783 95194 50473140
Progressive multifocal leukoencephalopathy 46.18 14.85 49 36741 11408 50556926
Dysuria 46.16 14.85 78 36712 28426 50539908
Ataxia 45.32 14.85 53 36737 13733 50554601
Rash 45.08 14.85 165 36625 437306 50131028
Burning sensation 44.96 14.85 101 36689 45345 50522989
Lymphocyte count abnormal 44.90 14.85 17 36773 613 50567721
Feeling abnormal 44.50 14.85 195 36595 125297 50443037
Diarrhoea 44.49 14.85 249 36541 588227 49980107
Haemoglobin urine present 44.24 14.85 18 36772 788 50567546
Sinusitis 43.58 14.85 36 36754 170522 50397812
Adverse drug reaction 43.13 14.85 112 36678 55110 50513224
Ankle fracture 41.30 14.85 54 36736 15668 50552666
Urine abnormality 41.07 14.85 35 36755 6203 50562131
Hemiparesis 40.93 14.85 61 36729 19987 50548347
Escherichia test positive 40.85 14.85 23 36767 2084 50566250
Urine odour abnormal 39.22 14.85 32 36758 5341 50562993
Extra dose administered 38.68 14.85 31 36759 5045 50563289
Nitrite urine present 38.55 14.85 17 36773 910 50567424
Invasive ductal breast carcinoma 38.53 14.85 33 36757 5888 50562446
Stomatitis 38.18 14.85 13 36777 101331 50467003
Vitamin B12 increased 38.15 14.85 15 36775 600 50567734
Relapsing-remitting multiple sclerosis 37.84 14.85 14 36776 473 50567861
Arthropathy 37.14 14.85 36 36754 157870 50410464
Weight increased 36.93 14.85 56 36734 201835 50366499
Drug interaction 36.87 14.85 55 36735 199566 50368768
Pneumonia 36.83 14.85 146 36644 378255 50190079
Tremor 36.59 14.85 173 36617 114730 50453604
Gastrointestinal haemorrhage 36.50 14.85 5 36785 73316 50495018
Optic neuritis 36.13 14.85 34 36756 6856 50561478
Pleural effusion 35.24 14.85 8 36782 81446 50486888
Drug hypersensitivity 35.03 14.85 82 36708 250928 50317406
General symptom 34.98 14.85 22 36768 2441 50565893
Pancytopenia 34.89 14.85 9 36781 84021 50484313
Swelling 34.58 14.85 58 36732 200814 50367520
Urinary tract infection pseudomonal 34.46 14.85 15 36775 778 50567556
Musculoskeletal disorder 34.29 14.85 52 36738 17297 50551037
Vomiting 33.66 14.85 197 36593 460561 50107773
Urinary tract infection bacterial 32.97 14.85 26 36764 4133 50564201
Wheelchair user 32.95 14.85 28 36762 4944 50563390
Drug intolerance 32.67 14.85 69 36721 219035 50349299
Abdominal pain 32.30 14.85 78 36712 236150 50332184
Acute disseminated encephalomyelitis 32.16 14.85 10 36780 196 50568138
Hip fracture 31.89 14.85 63 36727 25868 50542466
Platelet count decreased 31.45 14.85 17 36773 100709 50467625
Product use in unapproved indication 31.40 14.85 23 36767 115796 50452538
Cystitis 31.38 14.85 87 36703 44477 50523857
Pain 30.88 14.85 271 36519 578632 49989702
Respiratory failure 30.56 14.85 14 36776 91167 50477167
Prescribed underdose 30.39 14.85 47 36743 15902 50552432
Lymphocyte percentage decreased 30.32 14.85 21 36769 2739 50565595
Cognitive disorder 29.95 14.85 85 36705 44038 50524296
Tongue biting 29.87 14.85 16 36774 1314 50567020
Blood immunoglobulin M decreased 29.23 14.85 13 36777 710 50567624
B-lymphocyte count abnormal 28.95 14.85 7 36783 50 50568284
Blister 28.80 14.85 13 36777 85405 50482929
Glycosylated haemoglobin increased 28.75 14.85 37 36753 10569 50557765
Sensory disturbance 28.57 14.85 39 36751 11790 50556544
Muscle tightness 28.08 14.85 36 36754 10244 50558090
Thrombocytopenia 27.87 14.85 31 36759 127642 50440692
Cardiac arrest 27.79 14.85 13 36777 83638 50484696
Generalised tonic-clonic seizure 27.74 14.85 60 36730 26250 50542084
Hypokinesia 27.60 14.85 39 36751 12178 50556156
Intentional overdose 27.31 14.85 6 36784 62498 50505836
Headache 26.96 14.85 517 36273 506018 50062316
Invasive lobular breast carcinoma 26.85 14.85 12 36778 663 50567671
Overdose 26.78 14.85 20 36770 99707 50468627
Stress 26.71 14.85 93 36697 53700 50514634
Breast cancer 26.59 14.85 80 36710 42810 50525524
Diplopia 26.40 14.85 49 36741 19211 50549123
Coordination abnormal 26.32 14.85 37 36753 11497 50556837
Limb discomfort 26.20 14.85 56 36734 24301 50544033
Bacterial test positive 26.11 14.85 24 36766 4699 50563635
Incontinence 25.77 14.85 34 36756 9951 50558383
Decreased appetite 25.40 14.85 69 36721 200854 50367480
Protein urine present 25.30 14.85 25 36765 5352 50562982
Status epilepticus 24.84 14.85 39 36751 13367 50554967
Fatigue 24.84 14.85 681 36109 706920 49861414
Insurance issue 24.79 14.85 18 36772 2530 50565804
Immune reconstitution inflammatory syndrome 24.77 14.85 25 36765 5491 50562843
Hypoxia 24.27 14.85 4 36786 51119 50517215
Pyrexia 23.93 14.85 170 36620 380033 50188301
Urinary sediment present 23.90 14.85 16 36774 1975 50566359
Urine ketone body present 23.88 14.85 17 36773 2316 50566018
Hyponatraemia 23.67 14.85 21 36769 96118 50472216
Urinary retention 23.47 14.85 56 36734 26134 50542200
Oxygen saturation decreased 23.39 14.85 12 36778 73236 50495098
Paraparesis 23.37 14.85 16 36774 2048 50566286
Lower limb fracture 23.08 14.85 39 36751 14207 50554127
Infection 22.92 14.85 58 36732 172896 50395438
General physical health deterioration 22.81 14.85 43 36747 142391 50425943
Blood thyroid stimulating hormone decreased 22.67 14.85 21 36769 4151 50564183
Decreased interest 22.30 14.85 18 36772 2958 50565376
Hyperkalaemia 22.30 14.85 4 36786 48085 50520249
Skin laceration 22.24 14.85 45 36745 18797 50549537
Lymphocyte percentage abnormal 22.03 14.85 5 36785 26 50568308
Proteus test positive 21.63 14.85 7 36783 157 50568177
Hypersensitivity 21.54 14.85 82 36708 215079 50353255
International normalised ratio increased 21.34 14.85 3 36787 43149 50525185
Back pain 21.26 14.85 249 36541 219781 50348553
Urinary tract infection enterococcal 21.00 14.85 16 36774 2418 50565916
Feeling hot 20.53 14.85 69 36721 39133 50529201
Cystitis klebsiella 20.51 14.85 7 36783 186 50568148
Human papilloma virus test positive 20.46 14.85 9 36781 479 50567855
Red blood cell count abnormal 20.42 14.85 11 36779 914 50567420
Asthma 20.26 14.85 21 36769 89316 50479018
Urge incontinence 20.12 14.85 10 36780 703 50567631
Cardiac failure congestive 20.10 14.85 19 36771 84363 50483971
Impaired healing 20.05 14.85 13 36777 69773 50498561
Psoriasis 19.63 14.85 13 36777 68987 50499347
Initial insomnia 19.08 14.85 21 36769 5094 50563240
Speech disorder 19 14.85 63 36727 35485 50532849
Folliculitis 18.77 14.85 3 36787 39222 50529112
Therapeutic response changed 18.65 14.85 10 36780 823 50567511
Anaphylactic reaction 18.58 14.85 8 36782 54047 50514287
Metabolic acidosis 18.51 14.85 3 36787 38822 50529512
Urinary tract infection staphylococcal 18.45 14.85 7 36783 254 50568080
Peripheral swelling 18.41 14.85 82 36708 205854 50362480
Rectal haemorrhage 18.34 14.85 3 36787 38555 50529779
Hypoglycaemia 18.30 14.85 8 36782 53573 50514761
Cardiac failure 18.25 14.85 17 36773 76023 50492311
Depressed mood 17.92 14.85 60 36730 33963 50534371
Tachycardia 17.91 14.85 28 36762 99735 50468599
Bone pain 17.88 14.85 6 36784 47223 50521111
Living in residential institution 17.62 14.85 8 36782 459 50567875
Neutrophil percentage increased 17.34 14.85 15 36775 2712 50565622
Therapeutic product effect incomplete 17.09 14.85 25 36765 91490 50476844
Urinary tract disorder 17.00 14.85 14 36776 2366 50565968
Bladder dysfunction 16.78 14.85 9 36781 741 50567593
Mean cell haemoglobin decreased 16.67 14.85 16 36774 3307 50565027
CD4 lymphocyte percentage decreased 16.61 14.85 3 36787 3 50568331
Multiple organ dysfunction syndrome 16.44 14.85 8 36782 50329 50518005
Transferrin saturation decreased 16.44 14.85 8 36782 537 50567797
Haematocrit abnormal 16.41 14.85 9 36781 775 50567559
Citrobacter infection 16.38 14.85 7 36783 347 50567987
Vitamin D decreased 16.34 14.85 25 36765 8381 50559953
Postictal paralysis 16.33 14.85 5 36785 93 50568241
Disease progression 16.19 14.85 28 36762 95838 50472496
Intraductal proliferative breast lesion 16.16 14.85 14 36776 2536 50565798
Death 16.12 14.85 155 36635 325224 50243110
Hypertonic bladder 16.11 14.85 15 36775 2985 50565349
Arthritis 15.89 14.85 24 36766 86697 50481637
Electrocardiogram QT prolonged 15.84 14.85 9 36781 51877 50516457
Injection site scar 15.74 14.85 9 36781 840 50567494
Bacterial test 15.60 14.85 10 36780 1147 50567187
Cardio-respiratory arrest 15.54 14.85 10 36780 53882 50514452
Renal failure 15.53 14.85 34 36756 106599 50461735
B-lymphocyte count increased 15.50 14.85 5 36785 111 50568223
Dysarthria 15.49 14.85 61 36729 37342 50530992
Focal dyscognitive seizures 15.33 14.85 14 36776 2718 50565616
Decreased vibratory sense 15.31 14.85 6 36784 238 50568096
Haematochezia 15.21 14.85 5 36785 39877 50528457
Cough 15.09 14.85 108 36682 241156 50327178

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 899.12 20.15 288 12148 11131 29550960
Multiple sclerosis 432.08 20.15 139 12297 5415 29556676
Laboratory test abnormal 304.92 20.15 150 12286 18035 29544056
Balance disorder 298.62 20.15 187 12249 35983 29526108
Urinary tract infection 285.82 20.15 239 12197 72115 29489976
Gait disturbance 258.50 20.15 227 12209 73122 29488969
Fall 255.07 20.15 341 12095 176837 29385254
Muscle spasticity 222.67 20.15 82 12354 4801 29557290
Drug ineffective 197.09 20.15 454 11982 362716 29199375
Muscular weakness 146.15 20.15 154 12282 61898 29500193
Insomnia 130.39 20.15 173 12263 88588 29473503
Central nervous system lesion 129.84 20.15 58 12378 5590 29556501
Mobility decreased 126.71 20.15 97 12339 25683 29536408
Relapsing-remitting multiple sclerosis 121.62 20.15 33 12403 699 29561392
Gait spastic 118.83 20.15 32 12404 658 29561433
Therapy cessation 112.20 20.15 72 12364 14390 29547701
Needle fatigue 99.45 20.15 27 12409 573 29561518
B-lymphocyte count decreased 98.19 20.15 26 12410 500 29561591
Movement disorder 97.26 20.15 58 12378 10179 29551912
Ataxia 95.72 20.15 61 12375 12042 29550049
Memory impairment 95.68 20.15 96 12340 36374 29525717
Seizure 85.76 20.15 146 12290 92977 29469114
Secondary progressive multiple sclerosis 82.52 20.15 21 12415 343 29561748
Micturition urgency 81.63 20.15 41 12395 5132 29556959
Hypertonic bladder 75.88 20.15 27 12409 1429 29560662
Gait inability 72.88 20.15 61 12375 18314 29543777
Monoparesis 68.83 20.15 27 12409 1876 29560215
Pollakiuria 66.76 20.15 56 12380 16860 29545231
Flushing 66.43 20.15 71 12365 28921 29533170
Therapeutic response unexpected 64.50 20.15 42 12394 8596 29553495
Peroneal nerve palsy 63.53 20.15 28 12408 2611 29559480
Product substitution issue 59.83 20.15 41 12395 9131 29552960
Acute kidney injury 57.51 20.15 20 12416 265247 29296844
Trigeminal neuralgia 57.25 20.15 20 12416 1002 29561089
JC polyomavirus test positive 55.52 20.15 17 12419 559 29561532
Anaemia 53.38 20.15 10 12426 200941 29361150
Hypotension 53.08 20.15 9 12427 194345 29367746
Influenza like illness 52.68 20.15 58 12378 24412 29537679
Hypoaesthesia 52.02 20.15 86 12350 53381 29508710
Progressive multifocal leukoencephalopathy 49.94 20.15 36 12400 8683 29553408
Dizziness 48.33 20.15 182 12254 189502 29372589
Lymphocyte count decreased 43.78 20.15 47 12389 19224 29542867
Asthenia 43.32 20.15 192 12244 215058 29347033
Paraesthesia 42.49 20.15 79 12357 53766 29508325
Toxicity to various agents 41.36 20.15 11 12425 173650 29388441
Drug interaction 39.22 20.15 17 12419 197368 29364723
Urinary incontinence 38.86 20.15 41 12395 16440 29545651
Lymphocyte percentage decreased 37.85 20.15 18 12418 1999 29560092
Inappropriate schedule of product administration 37.30 20.15 67 12369 44405 29517686
Urine analysis abnormal 36.49 20.15 17 12419 1803 29560288
Progressive multiple sclerosis 36.32 20.15 10 12426 224 29561867
Dyspnoea 36.15 20.15 51 12385 326681 29235410
Nocturia 35.73 20.15 29 12407 8333 29553758
Off label use 35.25 20.15 45 12391 300755 29261336
Neutropenia 34 20.15 7 12429 131704 29430387
T-lymphocyte count decreased 33.65 20.15 9 12427 180 29561911
White blood cells urine positive 33.33 20.15 14 12422 1160 29560931
Dysarthria 33.16 20.15 52 12384 30859 29531232
Vitamin B12 increased 31.90 20.15 9 12427 221 29561870
Decreased vibratory sense 31.74 20.15 10 12426 362 29561729
Cognitive disorder 31.64 20.15 44 12392 23455 29538636
Renal failure 31.24 20.15 6 12430 118593 29443498
Walking aid user 30.24 20.15 14 12422 1463 29560628
CD8 lymphocytes decreased 30.23 20.15 7 12429 75 29562016
Cystitis 29.74 20.15 26 12410 8266 29553825
Thrombocytopenia 29.43 20.15 10 12426 134813 29427278
Adverse drug reaction 28.00 20.15 42 12394 23978 29538113
Bladder disorder 26.97 20.15 16 12420 2778 29559313
Back pain 25.02 20.15 97 12339 102187 29459904
Paraparesis 24.98 20.15 13 12423 1751 29560340
Burning sensation 24.76 20.15 32 12404 15906 29546185
Musculoskeletal stiffness 24.72 20.15 51 12385 37407 29524684
Pancytopenia 24.65 20.15 3 12433 83165 29478926
Dysstasia 24.59 20.15 26 12410 10448 29551643
Muscle spasms 24.13 20.15 71 12365 65011 29497080
General symptom 23.93 20.15 10 12426 818 29561273
Herpes zoster 23.57 20.15 44 12392 30008 29532083
Neurogenic bladder 23.32 20.15 12 12424 1578 29560513
Erectile dysfunction 23.17 20.15 33 12403 17976 29544115
Spinal cord injury cauda equina 21.32 20.15 6 12430 146 29561945
Temperature intolerance 21.30 20.15 14 12422 2907 29559184
Somatosensory evoked potentials abnormal 21.09 20.15 6 12430 152 29561939
Depression 21.01 20.15 81 12355 85066 29477025
Cardiac failure 20.89 20.15 4 12432 79283 29482808
Platelet count decreased 20.78 20.15 9 12427 104663 29457428
Urosepsis 20.61 20.15 24 12412 10722 29551369
Fatigue 20.44 20.15 213 12223 316608 29245483
T-lymphocyte count increased 20.32 20.15 3 12433 0 29562091
Vitamin B6 deficiency 20.28 20.15 6 12430 175 29561916
Generalised tonic-clonic seizure 20.24 20.15 32 12404 19107 29542984

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 2014.04 15.24 787 35764 40348 64421833
Urinary tract infection 1670.37 15.24 1230 35321 230366 64231815
Laboratory test abnormal 1620.75 15.24 582 35969 23481 64438700
Multiple sclerosis 684.40 15.24 292 36259 18649 64443532
Urine analysis abnormal 639.38 15.24 203 36348 5553 64456628
Fall 632.43 15.24 962 35589 415864 64046317
Balance disorder 608.79 15.24 449 36102 83477 64378704
Gait disturbance 413.58 15.24 498 36053 171657 64290524
Therapy cessation 327.42 15.24 213 36338 32276 64429905
Muscular weakness 314.77 15.24 374 36177 126964 64335217
Muscle spasticity 291.20 15.24 156 36395 16513 64445668
B-lymphocyte count decreased 262.10 15.24 71 36480 1090 64461091
Escherichia urinary tract infection 257.26 15.24 129 36422 11908 64450273
Seizure 223.51 15.24 365 36186 166527 64295654
Insomnia 194.50 15.24 378 36173 197458 64264723
Central nervous system lesion 187.81 15.24 104 36447 11745 64450436
Gait inability 181.19 15.24 167 36384 42201 64419980
Peroneal nerve palsy 165.91 15.24 74 36477 5247 64456934
Lymphocyte count decreased 157.91 15.24 152 36399 40547 64421634
Pollakiuria 154.04 15.24 134 36417 31396 64430785
Gait spastic 153.05 15.24 44 36507 848 64461333
Micturition urgency 150.82 15.24 86 36465 10273 64451908
Culture urine positive 146.53 15.24 63 36488 4088 64458093
Memory impairment 143.51 15.24 208 36343 85474 64376707
Secondary progressive multiple sclerosis 142.80 15.24 45 36506 1198 64460983
Toxicity to various agents 139.83 15.24 20 36531 363493 64098688
Urine leukocyte esterase positive 134.61 15.24 56 36495 3347 64458834
Relapsing-remitting multiple sclerosis 130.99 15.24 41 36510 1067 64461114
Dizziness 128.89 15.24 533 36018 429630 64032551
Hypoaesthesia 124.80 15.24 256 36295 138852 64323329
Mobility decreased 123.30 15.24 194 36357 85646 64376535
Therapeutic response unexpected 123.07 15.24 91 36460 16910 64445271
Movement disorder 122.87 15.24 101 36450 21899 64440282
Anaemia 118.40 15.24 34 36517 378646 64083535
Asthenia 110.31 15.24 507 36044 427537 64034644
Acute kidney injury 109.84 15.24 59 36492 449181 64013000
Urinary incontinence 107.48 15.24 117 36434 36034 64426147
T-lymphocyte count decreased 106.27 15.24 29 36522 458 64461723
JC polyomavirus test positive 105.81 15.24 36 36515 1226 64460955
Paraesthesia 102.77 15.24 232 36319 134290 64327891
T-lymphocyte count increased 102.66 15.24 21 36530 82 64462099
Dyspnoea 98.62 15.24 160 36391 718514 63743667
Inappropriate schedule of product administration 96.24 15.24 181 36370 92105 64370076
Trigeminal neuralgia 96.16 15.24 43 36508 3066 64459115
Off label use 93.40 15.24 134 36417 632672 63829509
White blood cells urine positive 90.00 15.24 49 36502 5349 64456832
Progressive multifocal leukoencephalopathy 88.05 15.24 77 36474 18155 64444026
Flushing 86.70 15.24 158 36393 78490 64383691
Ataxia 86.61 15.24 83 36468 22001 64440180
Febrile neutropenia 86.20 15.24 5 36546 187652 64274529
Hypotension 86.04 15.24 55 36496 380919 64081262
Needle fatigue 83.29 15.24 25 36526 563 64461618
CD8 lymphocytes decreased 83.14 15.24 21 36530 241 64461940
Completed suicide 82.46 15.24 14 36537 224400 64237781
CD4 lymphocytes increased 81.68 15.24 21 36530 260 64461921
Head injury 80.19 15.24 96 36455 32746 64429435
Rheumatoid arthritis 79.91 15.24 3 36548 164291 64297890
Neutropenia 77.67 15.24 20 36531 239604 64222577
Red blood cells urine positive 75.63 15.24 41 36510 4437 64457744
Lymphopenia 71.01 15.24 80 36471 25577 64436604
Product substitution issue 67.91 15.24 66 36485 17795 64444386
Drug interaction 66.90 15.24 64 36487 362019 64100162
Lymphocyte percentage decreased 66.07 15.24 38 36513 4611 64457570
Hypertonic bladder 65.37 15.24 34 36517 3384 64458797
Dysstasia 65.30 15.24 73 36478 23142 64439039
Vitamin B12 increased 64.25 15.24 21 36530 630 64461551
CD4 lymphocytes decreased 63.77 15.24 30 36521 2405 64459776
Neurogenic bladder 63.54 15.24 34 36517 3585 64458596
Dysuria 60.27 15.24 95 36456 41962 64420219
Monoparesis 58.46 15.24 30 36521 2904 64459277
Motor dysfunction 56.87 15.24 49 36502 11324 64450857
Progressive multiple sclerosis 56.29 15.24 20 36531 776 64461405
Walking aid user 55.56 15.24 38 36513 6243 64455938
Influenza like illness 53.43 15.24 112 36439 61590 64400591
Bladder disorder 52.70 15.24 40 36511 7727 64454454
Haemoglobin urine present 51.03 15.24 19 36532 844 64461337
Depression 49.92 15.24 221 36330 183070 64279111
Cystitis 49.91 15.24 88 36463 42587 64419594
Pancytopenia 48.29 15.24 11 36540 143298 64318883
Diarrhoea 47.88 15.24 229 36322 722475 63739706
Primary progressive multiple sclerosis 47.57 15.24 11 36540 84 64462097
Lymphocyte count abnormal 47.03 15.24 18 36533 863 64461318
Nitrite urine present 47.03 15.24 19 36532 1053 64461128
Gastrointestinal haemorrhage 46.96 15.24 9 36542 132303 64329878
Drug ineffective 45.80 15.24 698 35853 839549 63622632
Urine abnormality 45.77 15.24 36 36515 7326 64454855
Glycosylated haemoglobin increased 44.41 15.24 50 36501 15969 64446212
Product dose omission issue 44.40 15.24 223 36328 194524 64267657
Ankle fracture 44.39 15.24 48 36503 14662 64447519
Product use issue 43.14 15.24 16 36535 151699 64310482
Thrombocytopenia 43.14 15.24 38 36513 223763 64238418
Urinary tract infection bacterial 42.99 15.24 30 36521 5091 64457090
Magnetic resonance imaging abnormal 42.98 15.24 25 36526 3098 64459083
Escherichia test positive 42.59 15.24 24 36527 2801 64459380
Bacterial test positive 42.21 15.24 33 36518 6657 64455524
Joint swelling 42.20 15.24 36 36515 215346 64246835
Urinary tract infection pseudomonal 41.70 15.24 19 36532 1415 64460766
Loss of control of legs 41.64 15.24 20 36531 1679 64460502
Hip fracture 41.32 15.24 63 36488 27036 64435145
Invasive ductal breast carcinoma 41.07 15.24 29 36522 5013 64457168
Muscle spasms 40.65 15.24 173 36378 140850 64321331
Temperature intolerance 40.13 15.24 35 36516 8220 64453961
Blood thyroid stimulating hormone decreased 40.12 15.24 29 36522 5201 64456980
B-lymphocyte count abnormal 39.12 15.24 9 36542 67 64462114
Decreased appetite 38.99 15.24 62 36489 281227 64180954
Feeling abnormal 38.58 15.24 164 36387 133438 64328743
Dysarthria 38.32 15.24 96 36455 59310 64402871
Urine odour abnormal 38.31 15.24 28 36523 5108 64457073
Status epilepticus 38.29 15.24 54 36497 21609 64440572
Blood immunoglobulin M decreased 38.27 15.24 16 36535 968 64461213
Platelet count decreased 38.08 15.24 24 36527 167687 64294494
Multiple organ dysfunction syndrome 37.95 15.24 6 36545 101407 64360774
Paraparesis 37.82 15.24 24 36527 3478 64458703
Epilepsy 37.73 15.24 68 36483 33463 64428718
Generalised tonic-clonic seizure 37.63 15.24 75 36476 39782 64422399
Renal failure 37.29 15.24 29 36522 181659 64280522
Pneumonia 37.17 15.24 177 36374 559399 63902782
Lower respiratory tract infection 36.79 15.24 5 36546 94609 64367572
General symptom 36.52 15.24 20 36531 2208 64459973
Tremor 36.10 15.24 173 36378 148057 64314124
Infusion related reaction 35.37 15.24 25 36526 164442 64297739
Drug hypersensitivity 35.29 15.24 50 36501 237765 64224416
Musculoskeletal disorder 35.21 15.24 47 36504 17859 64444322
Acute disseminated encephalomyelitis 35.04 15.24 11 36540 289 64461892
Nocturia 34.69 15.24 37 36514 11128 64451053
Hemiparesis 34.22 15.24 61 36490 29766 64432415
Urine ketone body present 34.06 15.24 22 36529 3285 64458896
Hyponatraemia 33.99 15.24 21 36530 148318 64313863
Protein urine present 33.87 15.24 33 36518 8923 64453258
Hyperkalaemia 33.59 15.24 8 36543 101121 64361060
Extra dose administered 33.58 15.24 29 36522 6721 64455460
Hypoxia 33.47 15.24 5 36546 88144 64374037
Immune reconstitution inflammatory syndrome 33.00 15.24 38 36513 12432 64449749
Cardiac failure 32.83 15.24 17 36534 132356 64329825
Abdominal pain 32.82 15.24 81 36470 312294 64149887
Respiratory failure 32.73 15.24 26 36525 161157 64301024
Neutrophil percentage increased 32.63 15.24 24 36527 4421 64457760
Cardiac arrest 32.37 15.24 24 36527 154040 64308141
Treatment failure 32.08 15.24 13 36538 116803 64345378
Cardiac failure congestive 32.04 15.24 17 36534 130563 64331618
Pleural effusion 31.76 15.24 16 36535 126543 64335638
Drug intolerance 31.54 15.24 36 36515 187956 64274225
Breast cancer 31.39 15.24 58 36493 29090 64433091
International normalised ratio increased 31.22 15.24 4 36547 79163 64383018
Cystitis klebsiella 30.98 15.24 10 36541 288 64461893
Prescribed underdose 30.51 15.24 44 36507 17971 64444210
Urosepsis 30.40 15.24 49 36502 22045 64440136
Metabolic acidosis 29.44 15.24 3 36548 70955 64391226
Cognitive disorder 29.42 15.24 83 36468 55004 64407177
Rhabdomyolysis 29.04 15.24 8 36543 91718 64370463
Weight increased 28.63 15.24 48 36503 213300 64248881
Overdose 28.50 15.24 29 36522 159537 64302644
Muscle tightness 27.96 15.24 33 36518 11082 64451099
Oxygen saturation decreased 27.73 15.24 13 36538 107163 64355018
Decreased vibratory sense 27.69 15.24 11 36540 583 64461598
Wheelchair user 27.24 15.24 22 36529 4650 64457531
Rash 27.05 15.24 151 36400 458398 64003783
Burning sensation 26.69 15.24 75 36476 49589 64412592
Back pain 26.68 15.24 237 36314 249934 64212247
Urinary tract infection enterococcal 26.63 15.24 18 36533 2900 64459281
Vitamin D decreased 26.62 15.24 27 36524 7660 64454521
Sensory disturbance 26.48 15.24 35 36516 13173 64449008
Hypoglycaemia 26.36 15.24 9 36542 89883 64372298
Exposure during pregnancy 26.08 15.24 6 36545 77669 64384512
CD8 lymphocyte percentage decreased 25.91 15.24 4 36547 0 64462181
Urinary sediment present 25.86 15.24 16 36535 2218 64459963
Stomatitis 25.83 15.24 15 36536 109590 64352591
Vomiting 25.66 15.24 195 36356 550922 63911259
CD8 lymphocytes increased 25.59 15.24 6 36545 49 64462132
Cardio-respiratory arrest 25.35 15.24 12 36539 98381 64363800
Invasive lobular breast carcinoma 25.09 15.24 10 36541 535 64461646
Pericarditis 25.04 15.24 3 36548 62513 64399668
Disease progression 25.01 15.24 26 36525 141654 64320527
Monocyte percentage increased 24.88 15.24 15 36536 1985 64460196
Insurance issue 24.76 15.24 17 36534 2809 64459372
Intentional overdose 24.71 15.24 10 36541 89934 64372247
Haematochezia 24.66 15.24 4 36547 66369 64395812
Coordination abnormal 24.54 15.24 36 36515 14928 64447253
Neutrophil count increased 24.52 15.24 48 36503 25126 64437055
Decreased interest 24.34 15.24 18 36533 3342 64458839
Lower limb fracture 24.29 15.24 34 36517 13511 64448670
Headache 23.94 15.24 427 36124 529040 63933141
Optic neuritis 23.64 15.24 26 36525 8090 64454091
Hepatic function abnormal 23.62 15.24 4 36547 64309 64397872
Arthralgia 23.25 15.24 151 36400 442109 64020072
General physical health deterioration 23.06 15.24 51 36500 204374 64257807
Human papilloma virus test positive 23.04 15.24 9 36542 456 64461725
Urinary tract disorder 23.03 15.24 17 36534 3149 64459032
Red blood cell count abnormal 22.90 15.24 12 36539 1212 64460969
Pyrexia 22.67 15.24 205 36346 558439 63903742
Vitamin B12 abnormal 22.40 15.24 6 36545 88 64462093
Lymphocyte percentage abnormal 22.00 15.24 5 36546 35 64462146
Glossodynia 21.72 15.24 5 36546 64691 64397490
Feeling hot 21.70 15.24 66 36485 45597 64416584
Urinary tract infection staphylococcal 21.58 15.24 10 36541 774 64461407
Visual impairment 21.42 15.24 91 36460 73986 64388195
Blood thyroid stimulating hormone increased 21.40 15.24 24 36527 7630 64454551
Tongue biting 21.38 15.24 13 36538 1747 64460434
Pulmonary oedema 21.20 15.24 9 36542 78665 64383516
CD4 lymphocyte percentage decreased 21.20 15.24 4 36547 9 64462172
Limb discomfort 20.86 15.24 47 36504 27128 64435053
Mean cell haemoglobin increased 20.65 15.24 16 36535 3186 64458995
Vitamin D abnormal 20.57 15.24 6 36545 122 64462059
Ascites 20.40 15.24 5 36546 61996 64400185
Blood urine present 20.38 15.24 37 36514 18303 64443878
Septic shock 20.18 15.24 18 36533 105419 64356762
Erectile dysfunction 20.16 15.24 30 36521 12597 64449584
Product use in unapproved indication 19.97 15.24 44 36507 176574 64285607
Urinary sediment abnormal 19.83 15.24 6 36545 139 64462042
B-lymphocyte count increased 19.75 15.24 6 36545 141 64462040
Glucose urine present 19.68 15.24 12 36539 1620 64460561
Blood pressure fluctuation 19.56 15.24 3 36548 51868 64410313
Spinal cord injury cauda equina 19.55 15.24 6 36545 146 64462035
Dysgraphia 19.51 15.24 16 36535 3455 64458726
Expanded disability status scale score increased 19.42 15.24 8 36543 466 64461715
Sinusitis 19.41 15.24 33 36518 145895 64316286
Vitamin B6 deficiency 19.40 15.24 7 36544 284 64461897
Mean cell haemoglobin decreased 19.08 15.24 17 36534 4105 64458076
Proteus test positive 18.84 15.24 7 36544 309 64461872
Contraindicated product administered 18.79 15.24 20 36531 107809 64354372
Urinary retention 18.77 15.24 66 36485 49135 64413046
Fear of falling 18.77 15.24 8 36543 508 64461673
Asthma 18.53 15.24 16 36535 95209 64366972
Skin laceration 18.48 15.24 42 36509 24375 64437806
Citrobacter infection 18.47 15.24 9 36542 780 64461401
Rectal haemorrhage 18.46 15.24 6 36545 61811 64400370
Somatosensory evoked potentials abnormal 18.33 15.24 6 36545 181 64462000
Anaphylactic reaction 18.27 15.24 8 36543 68656 64393525
Neuropathy peripheral 18.13 15.24 24 36527 117501 64344680
Road traffic accident 18.08 15.24 48 36503 30697 64431484
Coma 17.95 15.24 14 36537 87601 64374580
Crystal urine present 17.85 15.24 12 36539 1917 64460264
Bacterial test 17.51 15.24 10 36541 1197 64460984
Swelling 17.23 15.24 41 36510 160177 64302004
Stress 17.22 15.24 74 36477 60460 64401721
Urobilinogen urine increased 17.21 15.24 8 36543 624 64461557
Electrocardiogram QT prolonged 17.17 15.24 12 36539 79436 64382745
Therapeutic product effect incomplete 17.15 15.24 20 36531 103462 64358719
Haemorrhage 17.13 15.24 12 36539 79339 64382842
Rash maculo-papular 17.11 15.24 3 36548 47023 64415158
Musculoskeletal stiffness 17.08 15.24 124 36427 123082 64339099
Tibia fracture 17.04 15.24 17 36534 4728 64457453
Full blood count abnormal 17.04 15.24 46 36505 29711 64432470
Nephrolithiasis 17.01 15.24 59 36492 43624 64418557
Diplopia 16.99 15.24 43 36508 26722 64435459
Therapy interrupted 16.90 15.24 36 36515 20000 64442181
Speech disorder 16.80 15.24 63 36488 48378 64413803
Angioedema 16.77 15.24 7 36544 61814 64400367
Chronic kidney disease 16.64 15.24 6 36545 57913 64404268
White matter lesion 16.62 15.24 11 36540 1711 64460470
Therapeutic response changed 16.59 15.24 9 36542 975 64461206
Lactic acidosis 16.59 15.24 7 36544 61403 64400778
Lymphocyte count increased 16.37 15.24 17 36534 4958 64457223
Urine uric acid decreased 16.36 15.24 5 36546 120 64462061
Wrist fracture 16.31 15.24 24 36527 9977 64452204
Dyspnoea exertional 16.12 15.24 11 36540 73719 64388462
Focal dyscognitive seizures 16.09 15.24 14 36537 3276 64458905
Hypokalaemia 15.82 15.24 28 36523 121875 64340306
COVID-19 15.82 15.24 76 36475 65064 64397117
Renal impairment 15.79 15.24 33 36518 134984 64327197
Respiratory distress 15.76 15.24 5 36546 52326 64409855
Transferrin saturation decreased 15.74 15.24 8 36543 759 64461422
Streptococcal urinary tract infection 15.63 15.24 6 36545 290 64461891
CD4 lymphocytes abnormal 15.60 15.24 4 36547 49 64462132
Urinary tract obstruction 15.56 15.24 15 36536 4002 64458179
Incontinence 15.55 15.24 26 36525 12055 64450126
Maternal exposure during pregnancy 15.39 15.24 19 36532 95865 64366316
Urine cannabinoids increased 15.28 15.24 3 36548 9 64462172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07XX07 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA MoA N0000175448 Potassium Channel Antagonists
FDA EPC N0000192795 Potassium Channel Blocker
CHEBI has role CHEBI:33289 avicides
CHEBI has role CHEBI:71031 orphan drugs
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026902 Potassium Channel Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple sclerosis indication 24700007 DOID:2377
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated potassium channel Ion channel BLOCKER IC50 4.05 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily C member 1 Ion channel BLOCKER IC50 4.50 IUPHAR
Potassium voltage-gated channel subfamily C member 2 Ion channel BLOCKER IC50 4.60 IUPHAR

External reference:

IDSource
4029704 VUID
N0000180628 NUI
D04127 KEGG_DRUG
4025700 VANDF
4025705 VANDF
4029704 VANDF
C0000477 UMLSCUI
CHEBI:34385 CHEBI
4AP PDB_CHEM_ID
CHEMBL284348 ChEMBL_ID
DB06637 DRUGBANK_ID
2416 IUPHAR_LIGAND_ID
BH3B64OKL9 UNII
1727 PUBCHEM_CID
897018 RXNORM
170373 MMSL
26967 MMSL
NOCODE MMSL
d07546 MMSL
006829 NDDF
413355004 SNOMEDCT_US
80994002 SNOMEDCT_US
D015761 MESH_DESCRIPTOR_UI
7283 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0479 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0509 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA authorized generic 27 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2533 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 16729-292 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
DALFAMPRIDINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-275 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine Human Prescription Drug Label 1 62756-429 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
DALFAMPRIDINE Human Prescription Drug Label 1 65862-863 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections